PT  - JOURNAL ARTICLE
AU  - YOSHIHISA ARAKAKI
AU  - TAKURO ARIGA
AU  - JOICHI HEIANNA
AU  - YUKO SHIMOJI
AU  - TADAHARU NAKASONE
AU  - YUSUKE TAIRA
AU  - TOMOKO NAKAMOTO
AU  - TAKUMA OOYAMA
AU  - WATARU KUDAKA
AU  - ITOMI KANESHIMA
AU  - KUMIKO NISHIHIRA
AU  - KEIKO MEKARU
AU  - YOICHI AOKI
TI  - Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin
AID  - 10.21873/invivo.12096
DP  - 2020 Sep 01
TA  - In Vivo
PG  - 2739--2743
VI  - 34
IP  - 5
4099  - http://iv.iiarjournals.org/content/34/5/2739.short
4100  - http://iv.iiarjournals.org/content/34/5/2739.full
SO  - In Vivo2020 Sep 01; 34
AB  - Background/Aim: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT). Patients and Methods: Thirty patients with stage IB–IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel. Results: A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TP-CCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively. Conclusion: TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS.